Targets › CHRM
1 program from 1 company in 1 trial: 1 Phase 2; Oncology.
Open in Phaseline: the race on CHRM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Susan E. Bates | Bethanechol Muscarinic acetylcholine receptor agonist (parasympathomimetic agent) | CHRM | Phase 2 | Pancreas Cancer | – |
Pancreas Cancer (1)
small molecule (1)
Susan E. Bates (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.